TAFRO Syndrome with Renal Thrombotic Microangiopathy: Insights into the Molecular Mechanism and Treatment Opportunities
Open Access
- 11 June 2021
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (12) , 6286
Abstract
TAFRO syndrome is an extremely rare form of idiopathic MCD, characterized by thrombocytopenia, anasarca, fever, reticulin fibrosis on bone marrow biopsy, and organomegaly. Like idiopathic MCD, renal involvement is also a common presentation in patients with TAFRO syndrome. Furthermore, membranoproliferative glomerulonephritis (MPGN)-like injury and thrombotic microangiopathy (TMA) are the most reported histopathologic findings of renal biopsy. Several molecular mechanisms have been previously postulated in order to explain the TAFRO syndrome symptoms, including abnormal production of interleukin-6 (IL-6), vascular endothelial growth factor (VEGF), etc. The role of these cytokines in renal injury, however, is not well understood. The aim of this review article is to summarize the latest knowledge of molecular mechanisms behind the TAFRO syndrome and their potential role in renal damage.Keywords
This publication has 61 references indexed in Scilit:
- The spectrum of renal thrombotic microangiopathy in lupus nephritisArthritis Research & Therapy, 2013
- Targeting Interleukin-6: All the Way to Treat Autoimmune and Inflammatory DiseasesInternational Journal of Biological Sciences, 2012
- Castleman's Disease: From Basic Mechanisms to Molecular TherapeuticsThe Oncologist, 2011
- Thrombotic microangiopathy and the antiphospholipid syndromeLupus, 2010
- Thrombomodulin Mutations in Atypical Hemolytic–Uremic SyndromeNew England Journal of Medicine, 2009
- Shiga toxin-associated hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: distinct mechanisms of pathogenesisKidney International, 2009
- VEGF Inhibition and Renal Thrombotic MicroangiopathyNew England Journal of Medicine, 2008
- Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman diseaseBlood, 2005
- Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinomaJournal of Biomedical Science, 2004
- Interleukin 6 Induces the Expression of Vascular Endothelial Growth FactorJournal of Biological Chemistry, 1996